Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
EBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Consolidated Net Income (2016 - 2024)

Lifecore Biomedical, Inc. \De\ has reported Consolidated Net Income over the past 15 years, most recently at $3000.0 for Q2 2024.

  • Quarterly results put Consolidated Net Income at $3000.0 for Q2 2024, up 100.13% from a year ago — trailing twelve months through Feb 2025 was $3000.0 (down 99.22% YoY), and the annual figure for FY2024 was $2.7 million, up 107.59%.
  • Consolidated Net Income for Q2 2024 was $3000.0 at Lifecore Biomedical, Inc. \De\, down from $847000.0 in the prior quarter.
  • Over the last five years, Consolidated Net Income for LFCR hit a ceiling of $1.8 million in Q3 2023 and a floor of -$51.6 million in Q2 2022.
  • Median Consolidated Net Income over the past 5 years was -$3.2 million (2020), compared with a mean of -$9.9 million.
  • Biggest five-year swings in Consolidated Net Income: crashed 2410.57% in 2020 and later surged 143.44% in 2023.
  • Lifecore Biomedical, Inc. \De\'s Consolidated Net Income stood at -$4.0 million in 2020, then plummeted by 1039.91% to -$46.0 million in 2021, then surged by 92.17% to -$3.6 million in 2022, then surged by 99.33% to -$24000.0 in 2023, then surged by 112.5% to $3000.0 in 2024.
  • The last three reported values for Consolidated Net Income were $3000.0 (Q2 2024), $847000.0 (Q1 2024), and -$24000.0 (Q4 2023) per Business Quant data.